MARKET

ITCI

ITCI

INTRA CELLULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.67
+1.40
+4.21%
After Hours: 34.67 0 0.00% 16:01 03/05 EST
OPEN
33.60
PREV CLOSE
33.27
HIGH
34.81
LOW
32.24
VOLUME
778.25K
TURNOVER
--
52 WEEK HIGH
40.01
52 WEEK LOW
10.94
MARKET CAP
2.81B
P/E (TTM)
-10.7129
1D
5D
1M
3M
1Y
5Y
--Analyst Actions: RBC Capital Adjusts Price Target on Intra-Cellular Therapies to $42 From $40, Maintains Outperform Rating
MT Newswires · 02/26 08:56
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 02/26 00:07
8-K: Intra-Cellular Therapies, Inc.
(EDGAR Online via COMTEX) -- false 0001567514 0001567514 2021-02-25 2021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 16:08
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 02/25 14:05
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 02/25 13:08
Intra-Cellular Therapies Q4 EPS $(0.76) Beats $(0.85) Estimate, Sales $12.45M Beat $11.84M Estimate
Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.85) by 10.59 percent. This is a 2.7 percent decrease over losses of $(0.74) per share
Benzinga · 02/25 13:02
BRIEF-Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2020 Results
reuters.com · 02/25 12:53
10-K: INTRA-CELLULAR THERAPIES, INC.
(EDGAR Online via COMTEX) -- Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of the...
Edgar Online - (EDG = 10Q, 10K) · 02/25 12:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ITCI. Analyze the recent business situations of INTRA CELLULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ITCI stock price target is 51.38 with a high estimate of 81.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 287
Institutional Holdings: 71.58M
% Owned: 88.46%
Shares Outstanding: 80.92M
TypeInstitutionsShares
Increased
59
6.14M
New
80
457.27K
Decreased
49
2.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chief Financial Officer/Senior Vice President - Finance/Treasurer/Assistant Secretary
Lawrence Hineline
Executive Vice President/General Counsel/Secretary
Michael Halstead
Executive Vice President
Mark Neumann
Senior Vice President/Chief Scientific Officer
Robert Davis
Senior Vice President
John Bardi
Senior Vice President
Michael Olchaskey
Senior Vice President
Kimberly Vanover
Other
Suresh Durgam
Lead Director/Independent Director
Robert Van Nostrand
Director/Chief Executive Officer/President/Chairman
Sharon Mates
Independent Director
Christopher Alafi
Independent Director
Richard Lerner
Independent Director
Joel Marcus
Independent Director
Rory Riggs
No Data
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.